Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bi-44370. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 20/20 | 1.00 |
| ▸ | RAMP1 | O60894 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bi-44370 SCHEMBL2088321 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CYP3A4 | |
| Bi-44370 SCHEMBL2088322 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2166657 | 0.96 | CALCRL (0.92) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2166662 | 0.96 | CALCRL (0.92) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13712916 | 0.95 | CALCRL (0.91) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13712917 | 0.94 | CALCRL (0.90) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL14016414 | 0.94 | CALCRL (0.90) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL12773023 | 0.94 | CALCRL (0.89) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2164024 | 0.94 | CALCRL (0.88) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2164025 | 0.94 | CALCRL (0.88) | CALCRLRAMP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109188-A1 | PREVENTATIVE TREATMENT OF MIGRAINE | CGRP DIAGNOSTICS GMBH (CH) | 2025-04-03 | — | — | US | claimed |
| US-20240383973-A1 | METHODS FOR TREATING CALCITONIN GENE-RELATED PEPTIDE (CGRP) - EXPRESSING CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2024-11-21 | — | — | US | claimed |
| WO-2024218541-A1 | TREATMENT OF MIGRAINE | HASLETON MARK (IL) | 2024-10-24 | — | — | WO | claimed |
| WO-2023146866-A2 | METHODS FOR TREATING CALCITONIN GENE-RELATED PEPTIDE (CGRP) - EXPRESSING CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-08-03 | — | — | WO | claimed |
| WO-2023026205-A1 | PREVENTATIVE TREATMENT OF MIGRAINE | CGRP DIAGNOSTICS GMBH (CH) | 2023-03-02 | — | — | WO | claimed |
| US-20240383973-A1 | METHODS FOR TREATING CALCITONIN GENE-RELATED PEPTIDE (CGRP) - EXPRESSING CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2024-11-21 | — | — | US | disclosed |
| CN-117999078-A | Treatment and/or reduction of migraine occurrence | CGRP诊断公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20240083870-A1 | SALTS OF PYRIDINYLMETHYLENEPIPERIDINE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-03-14 | — | — | US | disclosed |
| US-11858910-B2 | Pyridinylmethylenepiperidine derivatives and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| EP-4271671-A1 | SALTS OF PYRIDINYLMETHYLENEPIPERIDINE DERIVATIVES AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023146866-A2 | METHODS FOR TREATING CALCITONIN GENE-RELATED PEPTIDE (CGRP) - EXPRESSING CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-114685444-B | Salts of pyridyleiperidine derivatives and uses thereof | 广东东阳光药业有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-110272425-B | Pyridyloxyl octahydropyrrolo [3,4-c ] pyrrole derivatives and uses thereof | 广东东阳光药业有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-114728929-A | Pyridine methylene piperidine derivatives and use thereof | 广东东阳光药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-110437205-B | Pyridinonylpiperidine derivatives and use thereof | 广东东阳光药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022143622-A1 | SALTS OF PYRIDINYLMETHYLENEPIPERIDINE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-07-07 | — | — | WO | disclosed |
| CN-114685443-A | Salts of pyridinylalkenylpiperidine derivatives and use thereof | 广东东阳光药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114685444-A | Salts of pyridinylalkenylpiperidine derivatives and use thereof | 广东东阳光药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114685442-A | Salts of pyridinylalkenylpiperidine derivatives and use thereof | 广东东阳光药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114685440-A | Salts of pyridinylalkenylpiperidine derivatives and use thereof | 广东东阳光药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083870-A1 | SALTS OF PYRIDINYLMETHYLENEPIPERIDINE DERIVATIVES AND USES THEREOF | HTR1F, HTR1A, HTR5A | CALCRL 159/4885RAMP1 73/4885CYP3A4 629/4885 |
| US-11858910-B2 | Pyridinylmethylenepiperidine derivatives and uses thereof | HTR1F, HTR1A, HTR5A | CALCRL 143/4885RAMP1 78/4885CYP3A4 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.